Komal Jhaveri, MD, FACP, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the role that patient comorbidities and treatment history play in the prioritisation of treatment options for patients with hormone receptor+/ HER2- (HR+/ HER-) metastatic breast cancer (mBC). Dr Jhaveri continues by questioning the potential impact of concurring PI3K/ AKT or germline B-cell receptor (BCR) mutations on the median progression-free survival (PFS) of patients known to harbor a ESFR1 mutation. This interview took place at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.